Viome Life Sciences, a preventative health technology company, has acquired Circulate Health, a pioneer in therapeutic plasma exchange outside the hospital setting. The move aims to integrate Viome’s molecular diagnostics and precision nutrition platform with Circulate’s physician-facilitated therapeutic plasma exchange and its network of clinical partners in the US.
The acquisition is expected to widen the scope of what clinicians can do with the information obtained from measuring biological aging, inflammation, metabolism, and the gut microbiome. Viome plans to offer more targeted interventions by bridging personalized nutrition with Circulate’s protocols that target healthspan and chronic disease.
Therapeutic plasma exchange is an established medical procedure that has been used in hospitals for over 50 years to treat a range of autoimmune and neurological conditions. Circulate Health is expanding its application toward longevity medicine by developing precise clinical protocols and adding to a growing body of peer-reviewed research.
Related: Bayer supports self care in health systems
Dr. Brad Younggren, MD, co-founder of Circulate Health, notes that longevity medicine has reached an inflection point. They can measure more about human biology than ever before, and the field now has real, proven ways to act on those insights. Younggren will join Viome as president of its newly formed clinical group, Viome PRO.
Viome notes that the services provided by Circulate Health, when paired with its precision nutrition diagnostics, are part of the company’s vision of a system where clinicians can measure, act, and measure again. This shift is expected to turn episodic care into measurable, longitudinal outcomes.
A recent study published in the Journal of Clinical Apheresis found that Circulate Health’s therapeutic plasma exchange procedure was associated with measurable reductions in circulating microplastic particles in the blood of patients with raised baseline levels. Earlier research published in Aging Cell associated Circulate’s plasma exchange protocol with an average 2.6-year reduction in biological age across a panel of molecular biomarkers.
Naveen Jain, founder of Viome, says that declining health is not inevitable. The future of medicine is making health something you can measure and improve, year after year. The acquisition of Circulate Health is seen as a step towards giving patients precision intervention and measurable outcomes.
Related: Saanroo treatment boosts key hormone levels
Viome’s approach to preventive health is more connected, less about any single test or treatment, and more about the system that ties them together and demonstrates they work.
Tailored nutrition and precision diagnostics are becoming increasingly common alongside traditional healthcare therapies. The Physicians Association for Nutrition International has urged integrating nutrition into healthcare, arguing it is essential to promote healthy diets while empowering professionals.
As the science of measuring biological aging, inflammation, metabolism, and the gut microbiome advances, companies like Viome are poised to play a significant role in shaping the future of medicine. By acquiring Circulate Health, Viome is taking a step towards creating a more connected and effective approach to preventive health.
